Back to search

University of Southampton

Synthesis, biodistribution and efficacy of monomeric and multimeric antisense oligonucleotides in visceral tissue and the central nervous system

Abstract

dc:description.abstract

Synthesis, biodistribution and efficacy of monomeric and multimeric<br/>antisense oligonucleotides in visceral tissue and the central nervous system<br/>Antisense oligonucleotides (ASOs) are a promising class of therapeutics for<br/>treating diseases of a genetic origin. ASOs are able to modulate the<br/>expression of disease-causing RNA, interact with the immune system and<br/>affect the endogenous regulation of genes. ASOs are, however, poorly taken<br/>up into some tissue types which limits their potential therapeutic benefit.<br/>This work aimed to improve the biodistribution and efficacy of antisense<br/>oligonucleotides by synthesising them as dendrimers - discrete structures<br/>comprising multiple oligonucleotides around a central core. Hence, the<br/>various synthetic approaches are described for attempts to access these<br/>molecules, their effects on in vitro and in vivo distribution and silencing<br/>of the long non-coding RNA MALAT1. It is demonstrated that larger<br/>dendrimers are more rapidly taken up into cultured cells than monomeric<br/>oligomers and that the compounds distribute differently in the mouse.<br/>Nevertheless, silencing efficacy both in vitro and in vivo seems to peak<br/>with monomeric or dimeric structures. It is anticipated that the rapid<br/>uptake of these dendrimers may be able to be translated into improved<br/>silencing by modifying their chemistry in the future.<br/><br/>To adequately assay the biodistribution of these oligonucleotides, the<br/>available techniques discussed in the literature are compared. Dissatisfied<br/>with the current state of the art, the process of preparing a polyclonal<br/>antibody directed against the chemically modified backbone found in most<br/>therapeutic oligonucleotides is described. It is shown that the antibody<br/>generated is able to be used for immunohistochemistry and<br/>immunofluorescence, and that it shows promise for use as a quantitative<br/>assay for determining oligonucleotide concentration in tissue.<br/><br/>Finally, efforts in improving oligonucleotide chemistry and structure for<br/>silencing disease-causing RNA in the CNS are described. Using C9ORF72<br/>repeat-expanded Amyotrophic Lateral Sclerosis as a target disease, it is<br/>show that some oligonucleotides are intrinsically and surprisingly toxic on<br/>central administration and that this toxicity can be ameliorated by<br/>reduction of the phosphorothioate content of the backbone. The generation<br/>of a preclinical lead compound is described that will, building on this<br/>work, be screened for toxicity in non-human primates and advanced to a<br/>compassionate care trial in two patients, pending FDA approval.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D.
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Southampton
Year dc:date.issued
2018

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Moazami, Michael
Advisor dc:contributor.advisor
  • Watts, Jonathan K.

Rights

Language dc:language
English, eng

Chain of custody

source
Harvested from
University of Southampton
Base URL
eprints.soton.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Moazami, Michael. Synthesis, biodistribution and efficacy of monomeric and multimeric antisense oligonucleotides in visceral tissue and the central nervous system. doctoral thesis, University of Southampton, 2018.